Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Silencing P2Y<sub>12</sub> and P2Y<sub>13</sub> receptors rehabilitates the ADP-induced P2Y<sub>1</sub>-mediated osteogenic commitment of post-menopausal mesenchymal stromal cells

Bessa-Andrês C., Pinto-Cardoso R., Costa MA., Ferreirinha F., Marinhas J., Freitas R.

Laboratory Study on Hair & Scalp, published in Cell Commun Signal (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cell Commun Signal (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40713640
PMCID
PMC12291242
DOI
10.1186/s12964-025-02355-0
Citations
1

Abstract (original English)

Background Participation of ADP-sensitive metabotropic P2Y 1 , P2Y 12 and P2Y 13 receptors in human osteogenesis is controversial. Here, we investigated the variations in the expression and bone-forming properties of the P2Y 1 R in osteogenic-differentiating bone marrow-derived mesenchymal stromal cells (BM-MSCs) isolated from post-menopausal (Pm) women. We also tested whether observed P2Y 1 -related functional deficits result from the crosstalk with co-localized P2Y 12 and P2Y 13 receptors. Methods Pm BM-MSCs were cultured in an osteogenic-inducing medium in either the absence or presence of the selective P2Y 1 receptor agonist, MR2365; this compound was applied alone or after cells' incubation with selective P2Y 12 and P2Y 13 receptor antagonists or short hairpin RNAs designed to silence P2Y 12 or P2Y 13 receptors gene expression. Results BM-MSCs present immunoreactivity against all ADP-sensitive P2Y receptor subtypes, but their relative density varied among different Pm women and with the time of the cells in the culture. The P2Y 1 receptor agonist increased the alkaline phosphatase activity and bone nodule formation in BM-MSCs originating from a younger female, but it failed to promote the osteogenic differentiation of BM-MSCs from Pm women unless P2Y 12 or P2Y 13 receptors are blocked with AR-C66096 and MRS211, respectively. Silencing the P2Y 13 , but not the P2Y 12 , rece

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Cells, CulturedMesenchymal Stem CellsHumansReceptors, Purinergic P2Adenosine DiphosphateCell DifferentiationGene SilencingOsteogenesisPostmenopauseMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research